Orthopaedic Research Society

Valitor presented the its first preclinical data demonstration the potential of our anti-inflammatory product to treat arthritis at the Orthopaedic Research Society conference in New Orleans, LA. This report demonstrated a substantial increase intra-articular half-life for our lead anti-inflammatory compound compared an equivalent unconjugated antibody. These data demonstrate how our technology to enhance the ability of anti-inflammatory antibodies to treat a variety of joint disorders.